Applied BioCode Corporation

Taiwan Stock Exchange 6598.TW

Applied BioCode Corporation Free Cash Flow for the year ending December 31, 2023: USD -6.89 M

Applied BioCode Corporation Free Cash Flow is USD -6.89 M for the year ending December 31, 2023, a -270.67% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Applied BioCode Corporation Free Cash Flow for the year ending December 31, 2022 was USD 4.04 M, a 166.58% change year over year.
  • Applied BioCode Corporation Free Cash Flow for the year ending December 31, 2021 was USD -6.06 M, a 2.40% change year over year.
  • Applied BioCode Corporation Free Cash Flow for the year ending December 31, 2020 was USD -6.21 M, a 45.06% change year over year.
  • Applied BioCode Corporation Free Cash Flow for the year ending December 31, 2019 was USD -11.31 M, a -13.23% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
SV Wall Street
Taiwan Stock Exchange: 6598.TW

Applied BioCode Corporation

CEO Dr. Winston Z. Ho Ph.D.
IPO Date Feb. 9, 2017
Location United States
Headquarters 12130 Mora Dr.
Employees 43
Sector Healthcare
Industries
Description

Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests. Further, the company offers fungal pathogen analyte specific reagents; human cytokine/chemokine multiplex kits to identify relevant biomarkers; mouse premixed multiplex kits and custom panels for enhancing flexibility in experimental design allowing the user to pick and choose their own analytes panel; and rat, monkey, canine, and non-human primate cytokine/chemokine multiplex kits. Additionally, the company provides BMB, calibration beads, and coupling kits for various bioassay applications; ELISA, a tool for the quantitative measurement of drug/protein/antibody levels in biological samples comprising cell lysate or serum; and various assay development services. Applied BioCode Corporation is based in Santa Fe Springs, California.

Similar companies

4142.TW

Adimmune Corporation

USD 0.68

1.94%

4133.TW

Abnova (Taiwan) Corporation

USD 0.90

0.67%

4104.TW

Excelsior Medical Co., Ltd.

USD 2.62

-0.35%

4737.TW

Bionime Corporation

USD 2.04

7.21%

4106.TW

Apex Medical Corp.

USD 0.74

0.06%

StockViz Staff

February 3, 2025

Any question? Send us an email